- Child Concussion: What To Know If Your Child Takes a Blow To the Head
- Wildfire Survivors Still Struggle With Basic Needs and Support
- Trump Administration Plans Deep Cuts to Federal Health Budget
- Top NIH Nutrition Researcher Quits, Citing Censorship Under Kennedy
- HHS Fires Team That Sets Federal Poverty Guidelines
- First Weight-Loss Pill From Lilly Shows Promising Results
- Allergy Expert Gives Tips On Seasonal Allergies
- Pregnancy Complications Affect Future Heart Health
- Stroke Among Younger Adults Linked To Non-Traditional Risks
- Psoriatic Arthritis Diagnoses Are Lagging, Patients Undertreated
Abuse-Resistant Prescription Painkiller Approved

The U.S. Food and Drug Administration has approved Hysingla ER (hydrocodone bitartrate), an abuse-resistant, extended release form of the painkiller hydrocodone (best known as Vicodin).
The drug is sanctioned for long-term severe pain that requires daily, around-the-clock treatment. The tablet is difficult to crush, break or dissolve, making it resistant to abuse, the agency said Thursday in a news release.
But the medication can still be abused, and an overdose can lead to death, the FDA warned.
Hysingla ER shouldn’t be used for “as-needed” pain relief, the agency added.
The drug’s safety and effectiveness were evaluated in clinical studies involving 905 people with chronic lower-back pain. The most common side effects were constipation, nausea, fatigue, upper respiratory tract infection, dizziness and headache.
The FDA said it has ordered a post-marketing study to further assess the drug’s potential for abuse. Hysingla ER is produced by Purdue Pharma, based in Stamford, Conn.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.